Background: Primary cardiac tumors are rare, but few studies have examined the relationship between risk factors and the prognosis. The aim of this study was to provide a survival analysis and risk factors for mortality in patients with primary cardiac tumors.
]INTRODUCTION
Primary cardiac tumors are extremely rare, with an autopsy incidence ranging from 0.001% to 0.030%. Almost 75% of cardiac tumors are benign, with myxomas the most frequent type; and nearly 25% of cardiac tumors are malignant, with sarcomas predominate [Butany 2005 ]. Of note, recent data from 18 cancer registries in the United States found that the incidence of primary malignant cardiac tumors was 34 cases per 100 million and increased obviously from 1973 to 2011 [Oliveira 2015] . As soon as the diagnosis with cardiac tumor is confirmed, the patient should be treated with surgical resection. Although surgical treatment is considered as a safe and highly effective strategy associated with good early and long-term outcomes [Bakaeen 2003; Yu 2014; Li 2017; Mkalaluh 2017; Saad 2018 ], a few literature reports revealed that some risk factors may affect the prognosis for patients with primary cardiac tumors, such as refusal of surgery [Yu 2014 ], operation method [Li 2017 ], pathology type [Bakaeen 2003; Simpson 2008; Oliveira 2015; Mkalaluh 2017; Nomoto 2017] , and New York Heart Association (NYHA) classification [Bakaeen 2003 ]. Conversely, age, sex, and race did not have a significant impact on survival rate [Saad 2018 ].
Considering the lack of data in the literature on the risk factors for prognosis of primary cardiac tumors, we retrospectively analyzed 71 patients in our single center over the past 11 years, and therefore sought to provide an in-depth analysis of survival and risk factors for mortality in patients with primary cardiac tumors.
MATERIALS AND METHODS

Study Population
We conducted a retrospective analysis of all cardiac tumors in the patient database of the People's Hospital of Xinjiang Uygur Autonomous Region from June 2006 to November 2017. The patients who had metastatic disease at the time of diagnosis were excluded. Finally, 71 consecutive patients with primary cardiac tumors were screened, including 60 cases of benign tumor and 11 cases of malignant tumor. This study protocol was approved by the Institutional Ethics Committee of People's Hospital of Xinjiang Uygur Autonomous Region.
Data Recording
Patient information was obtained from hospital records, including age, sex, NYHA classification, symptom, operation, and tumor characteristics. Pathological diagnosis of each patient who had received surgery was obtained from our hospital's pathology division, and the remaining patients who refused surgery were diagnosed by using echocardiography and magnetic resonance. Furthermore, long-term follow-up data were collected at outpatient clinics or in telephone interviews for all participants. Follow-up time was calculated either to death or to the last contact with the living patient, and surviving patients were censored at the last follow-up date. Median follow-up was 48.0 months (range, 3-120 months).
Trial Registration
This is a retrospective study, which was not registered in any trial registry.
RESULTS
Patient Characteristics
In this study, 71 patients met our inclusion criteria, and the baseline characteristics are described in Table 1 . The result showed that 84.51% of the primary cardiac tumors were benign (n = 60) and 15.49% of the primary cardiac tumors were malignant (n = 11). Both sex and age had no significant difference between benign and malignant groups (P >.05). According to NYHA classification grading of cardiac failure, benign and malignant tumors had no statistical significance between NYHA I and II (83.33% versus 72.73%) and between NYHA III and IV (16.67% versus 27.27%).
Patients with cardiac tumors presented diverse symptoms: 11 patients (15.49%) had arrhythmia including atrial fibrillation (n = 5), ventricular tachycardia (n = 3), third-degree atrioventricular block (n = 3); 18 patients (25.35%) had leg edema; and 4 patients (5.63%) had peripheral thromboembolism that only happened in benign tumors. Of note, the percentage of arrhythmia (45.45% versus 10.00%, P = .011) and of leg edema (54.55% versus 20.00%, P = .025) in patients with malignant tumors were significantly higher than in those with benign tumors.
In the treatment, 66 patients underwent surgery, but 3 cases of benign tumor and 2 cases of malignant tumor chose conservative treatment, and the 2 malignant tumor cases who refused surgery died. At 11-year follow-up, only 1 patient from the benign tumor group died because of cardiac arrest, and 5 patients from the malignant tumor group died because of cardiac arrest (n = 2), malignant arrhythmia (n = 2), and cardiogenic shock (n = 1). Table 2 shows tumor location and pathology of cardiac tumors in detail. A total of 77 lesions were visualized by using echocardiography and magnetic resonance in 71 patients. Tumors that occurred in 2 chambers were seen in 6 patients, including 3 cases in the left atrium and right atrium, 2 cases in the right atrium and right ventricle, 1 case in the left atrium and left ventricle, whereas 65 patients had a tumor in a single chamber. Compared with benign tumors, the percentage of biatrial lesions (27.27% versus 5.0%) in malignant tumors was significantly higher (P = .044). In cases of benign tumors, the left atrium was the most frequent location (n = 55, 87.30%), whereas malignant tumors occurred in any chamber of the heart, but are frequently found in the pericardium (n = 5, 45.45%) and right atrium (n = 4, 36.36%). The most common benign tumor was myxoma (n = 54, 90.00%), The Heart Surgery Forum #2018-2271
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followed by fibroelastoma (n = 3, 5.00%) and lipoma (n = 3, 5.00%). Moreover, cardiac sarcomas (n = 8, 72.73%) formed the largest group of malignant tumors, followed by mesothelioma (n = 3, 27.27%).
Mortality
At the last follow up of 11 years, malignant tumors had a higher mortality rate than benign tumors (45.45% versus 1.67%, P <.001). The survival curves showed that sex, NYHA classification, leg edema, and peripheral embolism had no statistically significant impact on survival ( Figures 1A-1D ). However, surgical treatment was associated with an improvement in the overall survival (logrank P = .009, Breslow P = .001, Figure 2A ), and patients with malignant cardiac tumors had significantly lower survival rate than those with benign tumors (log-rank P = .000, Breslow P = .000, Figure 2B ). Additionally, patients with biatrial lesions (log-rank P = .001, Breslow P = .009, Figure 2C ) and arrhythmia (log-rank P =.001, Breslow P = .001, Figure 2D ) had a significantly lower survival rate. As shown in Table 3 , the treatment choice, pathology type, and number of tumor lesions were the independent risk factors for mortality confirmed by the multivariate logistic regression analysis (P <.05).
DISCUSSION
In this study, we presented the patient characteristics, tumor lesions, and mortality of patients with primary cardiac tumors in our center. Compared with most of the previous reports, our research uniquely collected data on both benign and malignant cardiac tumors to provide a survival analysis and risk factors for prognosis.
In our data analysis, 84.51% of all the primary cardiac tumors were benign, which was similar to previous studies in Spain (84.90%) [Barreiro 2013 ], China (79.47%) [Yin 2016 ], and Germany (77.00 %) [Hoffmeier 2014 ]. In contrast, the remaining cardiac tumors are rare, and we found that a percentage of 15.49% of cardiac tumors were malignant and that various types of sarcoma together formed 72.73% of all malignant cardiac tumors, followed by mesothelioma. The percentage of malignant cardiac tumors in our study was consistent with other reports [Habertheuer 2015; Yin 2016; Mkalaluh 2017 ]. However, malignant cardiac tumors were frequently found in the right atrium [Hoffmeier 2014 ], but our results showed that the pericardium was the most often location, whereas the right atrium came in as the second. Interestingly, we also reported that the percentage of biatrial lesions in malignant tumors was significantly higher than in benign tumors. Patients with cardiac tumors often have diverse clinical presentations depending on the size and site of the tumor, regardless of tumor type [Roberts 1997 ]. According to the experience of Li et al, about 18 .7% of patients were asymptomatic [Li 2017] . Although symptoms such as dyspnea, angina, embolism, and arrhythmia are more frequently seen in cardiac tumors [Barnes 2014; Li 2017; Mkalaluh 2017] , we found that the main clinical presentations were arrhythmia, leg edema, and peripheral embolism. However, 5.63% of patients had peripheral embolism in our center; this was lower than the reports of Dias et al (19.80%) [Dias 2014 ] and Strecker et al (15.50%) [Strecker 2012 ]. Particularly, the events of peripheral embolism mostly happen in myxomas of benign tumors. As the reasons for it, Butany et al suggested that myxomas tend to cause embolisms because of their gelatinous structure [Butany 2005 ].
Since the first excision of intra-atrial myxoma was performed by Clarence Crafoord in 1954 [Chitwood 1992 ], cardiac tumors' resection gradually became a common, safe, and highly effective strategy associated with good early and long-term outcomes [Mkalaluh 2017; Li 2017; Kośmider 2013] .The rate of operation was 92.96% in our institution for both benign and malignant cardiac tumors. The overall cumulative survival after cardiac tumor excision at 30 days, 1 year, 5 years, and 15 years was 94%, 85%, 72%, and59%, respectively [Mkalaluh 2017 ]. Another report also showed that the 5-year survival rates were 83% for benign tumors, 30% for malignant tumors, and 26% for cardiac metastases [Hoffmeier 2014 ]. Excellent early and late surgical results can be obtained in patients with benign tumors. However, operation therapy of malignant cardiac tumors, which are difficult to excise completely, continues to have a poor prognosis [Bossert 2005; Barreiro 2013; Kośmider 2013; Yin 2016] . Indeed, Yu et al revealed that there were no differences in survival between refusal of surgery and surgery with positive surgical margins and that patients with negative surgical margins had a longer survival duration than patients who had positive surgical margins [Yu 2014 ]. In our study, we found that patients who refused surgery had a lower survival compared with operation receivers, and that such refusal was an independent risk factor for poor prognosis, which was consistent with a previous report [Yu 2014 ].
In addition, we also confirmed that malignant cardiac tumors and biatrial tumor lesions were independent risk factors for lower survival rate. Many reports have demonstrated that patients with malignant cardiac tumors had worse survival, especially angiosarcomas [Mkalaluh 2017; Nomoto 2017; Simpson 2008; Bakaeen 2003; Oliveira 2015] . To our knowledge, this is the first report of the association between biatrial tumor lesions and prognosis of cardiac tumors. Moreover, sex, NYHA grade, leg edema, and peripheral embolism had no effect on survival in our study, which was consistent with previous report [Saad 2018 ]. Conversely, Bakaeen et al reported that patients with NYHA III and IV had worse survival than those with NYHA I and II [Bakaeen 2003 ].
CONCLUSIONS
Primary cardiac tumors are rare and some risk factors may affect the prognosis. Our study suggests that conservative therapy, malignant cardiac tumors, and biatrial tumor lesions are independent risk factors for poor prognosis.
